Skip to main content

Table 4 Usage and dose of cinacalcet, phosphate binders (mg/day) and vitamin D (relative doses)* by PTH and P subgroup at baseline and the end of the efficacy assessment phase (EAP)

From: Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?

a. Target P ≤4.5 mg/dL

Mean (SE) dose [% of patients]

iPTH ≤300 pg/mL**

iPTH > 300 pg/mL

 

P ≤4.5 mg/dL

P > 4.5 mg/dL

P ≤4.5 mg/dL

P >4.5 mg/dL

BASELINE

-

-

N = 146

N = 393

Ca-based binders

-

-

1989 (215) [41]

1883 (121) [47]

Sevelamer

-

-

4137 (297) [48]

4876 (156) [55]

Vitamin D

-

-

1.5 (0.1) [70]

1.6 (0.1) [67]

Al-based binders

-

-

1874 (222) [18]

2450 (188) [20]

EAP

N = 130

N = 170

N = 50

N = 189

Cinacalcet

44 (4) [79]

54 (4) [84]

81 (15) [33]

96 (8) [34]

Ca-based binders

1844 (197) [63]

2331 (202) [71]

1888 (234) [36]

2218 (267) [48]

Sevelamer

4192 (428) [33]

4973 (250) [53]

4345 (480) [50]

4830 (256) [63]

Vitamin D

1.3 (0.1) [70]

1.6 (0.2) [77]

2.0 (0.3) [83]

1.8 (0.1) [78]

Al-based binders

2876 (605) [8]

2335 (319) [16]

2469 (557) [19]

2837 (369) [18]

b. Target P ≤5.5 mg/dL

Mean(SE) dose [% of patients]

iPTH ≤300 pg/mL**

iPTH > 300 pg/mL

 

P ≤5.5 mg/dL

P >5.5 mg/dL

P ≤5.5 mg/dL

P >5.5 mg/dL

BASELINE

-

-

N = 297

N = 242

Ca-based binders

-

-

1880 (142) [45]

1944 (159) [45]

Sevelamer

-

-

4434 (195) [48]

4960 (196) [58]

Vitamin D

-

-

1.6 (0.1) [70]

1.5 (0.1) [65]

Al-based binders

-

-

1995 (199) [14]

2518 (215) [25]

EAP

N = 209

N = 91

N = 111

N = 128

Cinacalcet

46 (3) [83]

60 (6) [81]

85 (10) [31]

99 (10) [36]

Ca-based binders

1975 (156) [64]

2458 (298) [76]

2079 (313) [47]

2238 (326) [44]

Sevelamer

4454 (279) [40]

5168 (344) [57]

4175 (347) [51]

5103 (292) [68]

Vitamin D

1.4 (0.1) [74]

1.6 (0.3) [74]

2.1 (0.2) [82]

1.6 (0.2) [77]

Al-based binders

2462 (410) [7]

2463 (384) [24]

2859 (519) [12]

2709 (390) [23]

  1. *Relative dose: dosage is based on conversion of each dose a patient received into a multiple of the defined minimum dose for a particular sterol: IV calcitriol = 0.5 μg 3 times per week (TIW), IV alfacalcidol = 1 μg TIW, IV paricalcitol = 2 μg TIW, oral calcitriol = 0.25 μg TIW, oral alfacalcidol = 0.25 μg once daily. Patients not receiving vitamin D at a timepoint are counted as having a zero dose at that timepoint. For Ca-or Aluminium-based P binders and sevelamer, dose is based on those actually receiving these agents.
  2. **Patients were required to have iPTH 300 –799 pg/mL at baseline but two patients with PTH <300 pg/mL were enrolled in error. For simplicity, data for these patients are not shown separately.
  3. SE: standard error.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us